How Much Does Actos (Pioglitazone) Cost in Louisiana in 2026?

Louisiana Cash-Pay Prices for Pioglitazone in 2026

The average cash price for generic pioglitazone across Louisiana retail pharmacies sits at approximately $15 per month in 2026. That figure covers a 30-count supply of 15 mg or 30 mg tablets, the two most commonly dispensed strengths. Brand-name Actos, manufactured by Takeda, lists at roughly $60 per month.

Price variation across the state is real but modest. Pharmacies in Baton Rouge, New Orleans, Shreveport, and Lafayette tend to cluster within $3 to $5 of that $15 average for generic tablets. Independent pharmacies sometimes undercut chains by $1 to $2, while grocery-store pharmacies (Albertsons, Winn-Dixie) may price slightly higher. The 45 mg strength can run $2 to $4 more per month than the 15 mg or 30 mg tablets because dispensing volume is lower.

Pioglitazone became available as a generic in 2012 after Takeda's U.S. patent expired, and generic competition has driven retail prices down steadily since. According to the FDA's Approved Drug Products database, multiple manufacturers hold active ANDAs for pioglitazone tablets. That competitive market is the single biggest reason the drug is affordable without insurance.

For patients filling at a 90-day quantity, many Louisiana pharmacies offer an additional 10% to 15% discount over three separate 30-day fills. Ask your pharmacist about 90-day pricing before assuming the monthly rate is your best option.

Louisiana Medicaid and Pioglitazone Coverage

Louisiana Medicaid does not cover pioglitazone on its preferred drug list as of 2026. This applies to both brand Actos and generic formulations.

That exclusion affects a large population. Louisiana expanded Medicaid under the Affordable Care Act in 2016, and roughly 800,000 residents are enrolled in Healthy Louisiana managed care plans administered by Aetna Better Health, AmeriHealth Caritas, Healthy Blue, and UnitedHealthcare Community Plan. None of these Medicaid managed care organizations (MCOs) include pioglitazone on their formularies without prior authorization, and prior authorization requests for pioglitazone are routinely denied because the Louisiana Department of Health's preferred alternatives for type 2 diabetes include metformin, sulfonylureas, and certain DPP-4 inhibitors.

A prescriber can submit a formal exception request if a patient has documented contraindications or treatment failures with preferred agents. The process requires clinical documentation showing intolerance or inadequate glycemic control on at least two preferred drugs. Approval rates for these exceptions are low, so patients and providers should plan for an alternative payment path.

For Medicaid enrollees who need pioglitazone specifically, the $15 per month generic cash price may actually be the most practical route. Some 503A compounding pharmacies in Louisiana offer pioglitazone at even lower cost, which we cover below. The Endocrine Society's 2024 clinical practice guideline on type 2 diabetes pharmacotherapy recognizes thiazolidinediones as a second-line option when metformin alone does not achieve target HbA1c, providing clinical justification for the drug even when formulary placement is unfavorable.

Commercial Insurance and Medicare Part D

Most commercial insurance plans available in Louisiana cover generic pioglitazone on Tier 1 or Tier 2 of their formularies. That typically translates to a copay of $0 to $15 per month, depending on your plan design.

Blue Cross and Blue Shield of Louisiana, the state's largest commercial insurer, lists generic pioglitazone on Tier 2 with a standard copay. Vantage Health Plan, a regional carrier based in Monroe, places it on Tier 1. CHRISTUS Health Plan and Ochsner Health Plan generally follow similar tiering for generic thiazolidinediones. Brand-name Actos, when covered at all, sits on Tier 3 or higher, with copays ranging from $30 to $60. Because the generic is bioequivalent and costs a fraction of the brand, most plans mandate generic substitution.

Medicare Part D plans in Louisiana almost universally cover generic pioglitazone. Under the 2025 Inflation Reduction Act provisions that cap annual Part D out-of-pocket spending at $2,000, pioglitazone's low cost means it contributes minimally to that threshold. Most Part D enrollees pay $0 to $10 per month for a 30-day supply.

Patients on high-deductible health plans (HDHPs) pay full cash price until meeting their deductible. For these patients, the $15 monthly generic cost is low enough that pioglitazone is one of the more affordable diabetes medications even during the deductible phase. In the PIVENS trial (N=247), pioglitazone 30 mg daily for 96 weeks significantly improved hepatic steatosis in patients with nonalcoholic steatohepatitis compared to placebo [1]. That trial provides evidence for off-label use in MASH, but insurance plans rarely cover pioglitazone for this indication without extensive prior authorization, and denials are common even with PIVENS data in the request.

Discount Programs and Savings Cards

Several pathways exist to reduce pioglitazone costs below the $15 average in Louisiana. Not all are worth the effort, so here is a direct comparison.

Pharmacy discount cards (GoodRx, RxSaver, SingleCare): These aggregate negotiated rates from pharmacy benefit managers. In Louisiana, GoodRx coupons bring generic pioglitazone to $4 to $9 at chains like Walmart, Costco, and CVS. Walmart's $4 generic list historically included pioglitazone 15 mg and 30 mg, though availability varies by location. These cards cannot be combined with insurance copays.

Takeda's savings card: Takeda offers a manufacturer savings card for brand-name Actos that can reduce copays to as low as $0 for commercially insured patients. The card does not apply to Medicaid, Medicare, or other government-funded programs. For patients already paying $15 or less for generic pioglitazone, the Takeda card offers no practical benefit. It becomes relevant only if a prescriber writes for brand Actos specifically and the plan charges a Tier 3 copay.

340B pharmacies: Louisiana has over 150 entities registered under the federal 340B Drug Pricing Program, including safety-net hospitals and federally qualified health centers (FQHCs). Patients receiving care at these facilities can access pioglitazone at 340B-discounted prices, which are typically 25% to 50% below wholesale acquisition cost. FQHCs in underserved parishes like East Carroll, Madison, and Tensas may offer pioglitazone at $0 to $5 for qualifying patients.

Patient assistance programs (PAPs): Takeda's patient assistance program, Takeda Help at Hand, provides brand Actos at no cost to uninsured patients meeting income requirements (generally below 250% of the federal poverty level). The FDA's resource page on patient assistance programs links to directories where Louisiana residents can search for eligibility.

Compounded Pioglitazone in Louisiana

Compounded pioglitazone is legal in Louisiana through 503A-licensed pharmacies. A 503A pharmacy compounds medications pursuant to individual prescriptions under state pharmacy board oversight.

The Louisiana Board of Pharmacy regulates compounding pharmacies under Louisiana Administrative Code Title 46, Part LIII. A 503A pharmacy in Louisiana may compound pioglitazone in alternative dosage forms (capsules, suspensions, or custom-dose tablets) when a prescriber determines that a commercially available formulation does not meet a patient's medical needs. Common reasons include dysphagia requiring a liquid formulation, dose titration below the commercially available 15 mg tablet, or allergy to an inactive ingredient in the manufactured product.

Cost for compounded pioglitazone varies by pharmacy but can be comparable to or slightly above the $15 monthly cash price for manufactured generic tablets, depending on the formulation complexity. Some Louisiana 503A pharmacies advertise compounded pioglitazone capsules at competitive pricing to attract cash-pay patients.

Two important distinctions: 503A compounding requires an individual prescription. 503B outsourcing facilities, which compound in bulk without patient-specific prescriptions, also operate in Louisiana but typically supply clinics and hospitals rather than individual patients. Both are regulated under different sections of the Federal Food, Drug, and Cosmetic Act. Compounded pioglitazone is not FDA-approved in the same way as manufactured tablets, though the active ingredient is identical.

A Cochrane systematic review of thiazolidinediones for type 2 diabetes confirmed pioglitazone's efficacy in reducing HbA1c by 0.8% to 1.0% from baseline, a benefit that applies regardless of whether the drug is dispensed as a manufactured tablet or a compounded formulation.

Telehealth Prescribing in Louisiana

Louisiana permits telehealth prescribing of pioglitazone. A physician or advanced practice provider licensed in Louisiana can evaluate a patient via synchronous video or audio-only telehealth, diagnose type 2 diabetes or confirm an existing diagnosis, and prescribe pioglitazone without an in-person visit.

Louisiana's telehealth parity law (La. R.S. 37:1271.1) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits for covered services. This means the consultation itself should not cost more via telehealth than in the office. Medicaid managed care plans in Louisiana also cover telehealth visits, even though they do not cover the pioglitazone prescription itself.

For patients in rural parishes, telehealth solves a real access problem. Louisiana has 22 parishes designated as Health Professional Shortage Areas (HPSAs) for primary care. A patient in a rural parish who would otherwise drive 45 minutes to an endocrinologist can receive a pioglitazone prescription via telehealth and fill it at their local pharmacy or by mail order.

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement on type 2 diabetes management supports the use of telehealth for ongoing diabetes medication management, including thiazolidinedione therapy, provided that appropriate laboratory monitoring (liver function tests, HbA1c) is performed at recommended intervals.

Prescribers should order baseline ALT before starting pioglitazone and recheck liver enzymes periodically. The FDA-approved prescribing information for pioglitazone notes that the drug should not be initiated if ALT exceeds 2.5 times the upper limit of normal [2]. This monitoring is easily coordinated through telehealth with local lab orders.

Pioglitazone Pricing Compared to Other Diabetes Drugs in Louisiana

Pioglitazone is among the least expensive diabetes medications available in Louisiana. Here is how it compares on a monthly cash-pay basis for commonly prescribed alternatives.

Metformin (generic), the most prescribed first-line agent, costs $4 to $8 per month. Glipizide (generic sulfonylurea) runs $4 to $10. Pioglitazone at $15 per month falls in the same low-cost tier. By contrast, empagliflozin (Jardiance) costs $550 to $600 per month without insurance, and semaglutide (Ozempic) exceeds $900.

For patients whose HbA1c remains above target on metformin alone, adding pioglitazone is one of the most cost-effective intensification strategies available. The American Diabetes Association's Standards of Care 2024 identifies thiazolidinediones as a second-line option with proven cardiovascular and hepatic benefits in select populations [3]. The PROactive trial (N=5,238) showed that pioglitazone reduced the composite of all-cause mortality, nonfatal myocardial infarction, and stroke by 16% (HR 0.84 to 95% CI 0.72-0.98, P=0.027) in patients with type 2 diabetes and macrovascular disease [4].

Dr. Ralph DeFronzo of the University of Texas Health Science Center has stated: "Pioglitazone is the only oral diabetes drug with randomized trial evidence showing reduction in cardiovascular events and hepatic fibrosis. Its low cost makes it one of the most underutilized tools in diabetes care."

The Endocrine Society's guidelines note: "Thiazolidinediones should be considered in patients with type 2 diabetes and concurrent metabolic dysfunction-associated steatohepatitis (MASH), particularly when cost is a barrier to GLP-1 receptor agonist therapy" [5].

Safety Monitoring and Practical Considerations

Pioglitazone carries specific risks that affect how it should be prescribed and monitored, regardless of how it is obtained in Louisiana.

The drug causes fluid retention and can worsen or precipitate heart failure. The FDA's boxed warning contraindicates pioglitazone in NYHA Class III or IV heart failure [2]. Peripheral edema occurs in 4.8% of patients on pioglitazone monotherapy versus 1.2% on placebo. Weight gain averaging 2 to 3 kg over the first year is expected and reflects both fluid retention and increased subcutaneous adipose tissue.

Bone fracture risk is elevated in women taking pioglitazone. A meta-analysis published in the BMJ found a 1.5-fold increased risk of fractures in women but not men treated with thiazolidinediones [6]. Louisiana prescribers should assess bone density in postmenopausal women before initiating therapy.

Bladder cancer risk has been debated extensively. The FDA required a 10-year observational study (the Kaiser Permanente Northern California cohort) that ultimately showed no statistically significant association between pioglitazone use and bladder cancer at the population level, though the FDA safety communication acknowledged the data remained inconclusive for use beyond 5 years [7]. Patients with active bladder cancer should not take pioglitazone.

Baseline and periodic monitoring should include HbA1c every 3 months until stable, ALT at baseline and as clinically indicated, and assessment for signs of fluid retention or heart failure at each visit. For Louisiana patients obtaining pioglitazone via telehealth, lab orders can be sent to any Quest, LabCorp, or hospital-affiliated draw site in the state.

The standard starting dose is 15 mg or 30 mg once daily, with a maximum of 45 mg daily. Dose adjustments are not required for renal impairment, which simplifies prescribing in Louisiana's CKD population.